Article

Blockade of the KRAS-FOSL1 axis elicits DNA damage repair deficiency exploitable with local and systemic genotoxic therapies

2026-03-31

Abstract excerpt

<title>Abstract</title> <p>The clinical approval of direct KRAS inhibitors represents a milestone in precision oncology. Nonetheless, resistance heterogeneity limits durable clinical responses and impedes the nomination of a ‘‘one-size-fits-all’’ strategy for combination therapies. We circumvent this impasse by uncovering a core vulnerability elicited by KRAS blockade which transcends tissue origin, KRAS mutation...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dcd035ec-df4d-5acf-8eb9-724fbed2def6
DOI: 10.21203/rs.3.rs-9085811/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Blockade of the KRAS-FOSL1 axis elicits DNA damage repair deficiency exploitable with local and systemic genotoxic therapiesDOI 10.21203/rs.3.rs-9085811/v1Read

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.Semantic proximity Read

Targeting K-Ras-mediated DNA damage response in radiation oncology: Current status, challenges and future perspectivesSemantic proximity Read

Molecular landscape and clinical translation of DNA damage response alterations in solid tumors: A pan-cancer perspective on precision oncology.Semantic proximity Read

Targeting base excision repair in precision oncologySemantic proximity Read

FANCA Deficiency Induces Oncogenic R-Loop Dependent Synthetic Lethality with PARP1 InhibitorsSemantic proximity Read

MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.Semantic proximity Read

Changes in the Transcriptome and Synthetic Lethal Dependencies Following <i>KRAS</i> Mutant Expression Reveal Profound Tissue-SpecificitySemantic proximity Read

DNA repair in cancer: emerging targets for personalized therapySemantic proximity Read

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersSemantic proximity Read

Molecular targets that sensitize cancer to radiation killing: From the bench to the bedsideSemantic proximity Read

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcomaSemantic proximity Read

Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted TherapySemantic proximity Read